EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Taking stock of most-favored nation deals: how have markets reacted?

Noam Y Kirson iD, John M Dooley iD, Zhiqing Ge iD, Amitabh Chandra

Health Affairs Scholar · 03.07.2026 · 4 (7)

DOI: 10.1093/haschl/qxag176 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Affairs Scholar, online erschienen am 09.07.2026. Verfasst von Noam Y Kirson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Analysis Group, Inc., Boston, MA 02199, USA. Die Arbeit nennt 2 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The Trump Administration has pursued most-favored nation (MFN) drug pricing agreements with major pharmaceutical manufacturers, raising concerns about potential effects on pharmaceutical revenues, profitability, and innovation incentives. We examined whether equity markets interpreted these developments as positive or negative for the pharmaceutical sector.

Methods

We conducted an event study of 16 publicly traded pharmaceutical firms announcing MFN agreements. Abnormal returns and cumulative abnormal returns were estimated using standard market-model regressions based on each firm's historical relationship to the S&P 500. We analyzed market reactions surrounding “Liberation Day,” the date MFN letters were announced, and subsequent agreement announcements.

Results

The strongest market response was observed following the first MFN agreement announced by Pfizer, with largely positive market reactions across most of the pharmaceutical firms analyzed. In contrast, “Liberation Day” generated limited market reaction, while the MFN letters produced more modest negative effects.

Conclusion

Investors did not interpret the announced MFN agreements as materially value destructive, likely because the deals primarily targeted Medicaid and the limited TrumpRx platform, while also resolving some regulatory and tariff uncertainty. Future expansion of MFN may lead to different market reactions.

Schlagwörter

Stichwörter der Autor:innen

drug pricingevent studymost-favored nation

Autor:innen und Institutionen

  • Analysis Group, Inc., Boston, MA 02199, USA.
  • Analysis Group, Inc., Dallas, TX 75219, USA.
  • Harvard Kennedy School, Harvard University, Cambridge, MA 02138, USA.
  • Harvard Business School, Harvard University, Boston, MA 02163, USA.

ORCID-Profile: Noam Y Kirson, John M Dooley, Zhiqing Ge

Zitieren

APA

Kirson, N. Y., Dooley, J. M., Ge, Z., & Chandra, A. (2026). Taking stock of most-favored nation deals: how have markets reacted?. Health Affairs Scholar, 4(7). https://doi.org/10.1093/haschl/qxag176

Vancouver

Kirson NY, Dooley JM, Ge Z, Chandra A. Taking stock of most-favored nation deals: how have markets reacted?. Health Affairs Scholar. 2026;4(7). doi:10.1093/haschl/qxag176

BibTeX
@article{Kirson2026,
  author = {Kirson, Noam Y and Dooley, John M and Ge, Zhiqing and Chandra, Amitabh},
  title = {Taking stock of most-favored nation deals: how have markets reacted?},
  journal = {Health Affairs Scholar},
  year = {2026},
  volume = {4},
  number = {7},
  doi = {10.1093/haschl/qxag176}
}
Kostenlos starten →